Holen Sie sich die Stockscreener-App
1.75
0.57%
0.01
Schlusskurs vom Vortag:
$1.74
Offen:
$1.76
24-Stunden-Volumen:
1.09M
Relative Volume:
0.96
Marktkapitalisierung:
$74.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.92M
KGV:
-1.0194
EPS:
-1.7167
Netto-Cashflow:
$-26.53M
1W Leistung:
-4.37%
1M Leistung:
-14.63%
6M Leistung:
-52.32%
1J Leistung:
-35.19%
1-Tages-Spanne:
$1.75
$1.80
1-Wochen-Bereich:
$1.74
$1.90
52-Wochen-Spanne:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.75 | 74.45M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Why Annovis’ buntanetap pill is drawing fresh attention in Alzheimer’s race - AD HOC NEWS
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annovis Bio Inc Stock (US0360431013): Short Interest Climbs At End Of May - AD HOC NEWS
Annovis Bio Price, ANVS Price, Live Charts, and Marketcap - Coinbase
Annovis Regains NYSE Compliance Ahead of Listing Deadline - MyChesCo
Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Annovis Bio (ANVS) Faces Selling Pressure: Key Levels in Focus After 7.6% DeclineVolume Rate Change - thelegaladvocate.com
Annovis Bio regains NYSE listing compliance - MSN
Annovis Bio regains NYSE listing compliance By Investing.com - Investing.com Nigeria
Annovis Bio Regains NYSE Listing Compliance - The Manila Times
Annovis launches proposed public stock and warrant offering - MSN
Annovis Bio Analyst Ratings and Price Targets | NYSE:ANVS - Benzinga
Annovis Bio director Michael Hoffman buys $142,778 in shares By Investing.com - Investing.com Nigeria
Annovis Bio director Michael Hoffman buys $142,778 in shares - Investing.com UK
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Annovis Bio (ANVS) Rebounds 5.39%, Tests Key Resistance After Broader Market Upward MomentumCorrective Wave - thelegaladvocate.com
Director Michael Hoffman adds 76,344 Annovis Bio (ANVS) shares in open-market buys - Stock Titan
Annovis Bio prices $15 million public offering at $1.90 - Investing.com UK
Annovis Bio Announces Dilutive Equity Offering for Trials - TipRanks
Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity - TradingView
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Annovis Bio (NYSE: ANVS) raises $13.8M via 7.895M-share offering and warrants - Stock Titan
Annovis Bio Prices $15 Million Public Offering to Fund Neurodegenerative Disease Trials - MEXC
Annovis Bio slips after pricing $15M equity offering - MSN
Annovis announces pricing of $15.0 million public offering of common stock and accompanying warrants - marketscreener.com
Annovis Bio prices $15 million public offering at $1.90 By Investing.com - Investing.com South Africa
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - The Manila Times
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Press Release: Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall - Moomoo
Annovis Bio stock tumbles on public offering announcement By Investing.com - Investing.com India
Annovis Bio announces public offering of stock and warrants By Investing.com - Investing.com South Africa
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):